Skip to main content

#BrainHealth: another reason to hate margerine

Information rarely changes health outcomes on its own, which is why we need policy #PreventiveNeurology #BrainHealth

Although we have known about the cardiovascular risks associated with the consumption of trans fatty acids (TFAs) for decades little has been done by individuals to reduce their consumption. Therefore when the state of New York put in place restrictions on their use in 11 counties between 2007 and 2011 they set-up an experiment. This experiment now reports out: the study below included 25 counties and compared cardiovascular outcomes in the TFA non-restricted populations of 14 counties with the populations in the 11 TFA restricted counties. Three or more years after restrictions were put in place the people living in the counties with TFA restrictions experienced a significant decline in combined myocardial infarction and stroke events (-6.2%) compared with the TFA non-restricted populations. 


I sincerely hope you appreciate the significance of these findings? 

Lessons learnt:

1. Information alone rarely changes behaviour; policy and legislation are needed. 
2. TFA consumption is bad for you and increases your cardiovascular risk, which sets up a cascade of events that raises your risks of myocardial infarction, stroke and likely in time all-cause dementia.
3. If you want to optimise your brain health you need to eliminate TFAs from your diet. Easier said than done?

By Kagor at the Ukrainian language Wikipedia, CC BY-SA 3.0


Trans fats, or trans-unsaturated fatty acids, trans fatty acids, are a type of unsaturated fat that occur in small amounts in nature but became widely produced industrially from vegetable fats for use in margarine, snack food, packaged baked goods and frying fast food. Trans fat has been shown to consistently be associated, in an intake-dependent way, with increased risk of coronary heart disease.

In 2003 the World Health Organisation recommended that trans fats make up no more than 1% of a person's diet. In 2013, the United States Food and Drug Administration (FDA) issued a preliminary determination that partially hydrogenated oils (which contain trans fats) are not "generally recognised as safe", which was expected to lead to a ban on industrially produced trans fats from the American diet. On 16 June 2015, the FDA finalised its determination that trans fats are not generally recognised as safe, and set a three-year time limit for their removal from all processed foods.


Brandt et al. Hospital Admissions for Myocardial Infarction and Stroke Before and After the Trans-Fatty Acid Restrictions in New York. JAMA Cardiol. 2017 Apr 12. doi: 10.1001/jamacardio.2017.0491.

IMPORTANCE:  Trans-fatty acids (TFAs) have deleterious cardiovascular effects. Restrictions on their use were initiated in 11 New York State (NYS) counties between 2007 and 2011. The US Food and Drug Administration plans a nationwide restriction in 2018. Public health implications of TFA restrictions are not well understood.

OBJECTIVE: To determine whether TFA restrictions in NYS counties were associated with fewer hospital admissions for myocardial infarction (MI) and stroke compared with NYS counties without restrictions.

DESIGN, SETTING, AND PARTICIPANTS: We conducted a retrospective observational pre-post study of residents in counties with TFA restrictions vs counties without restrictions from 2002 to 2013 using NYS Department of Health's Statewide Planning and Research Cooperative System and census population estimates. In this natural experiment, we included those residents who were hospitalized for MI or stroke. The data analysis was conducted from December 2014 through July 2016.

EXPOSURE: Residing in a county where TFAs were restricted.

MAIN OUTCOMES AND MEASURES: The primary outcome was a composite of MI and stroke events based on primary discharge diagnostic codes from hospital admissions in NYS. Admission rates were calculated by year, age, sex, and county of residence. A difference-in-differences regression design was used to compare admission rates in populations with and without TFA restrictions. Restrictions were only implemented in highly urban counties, based on US Department of Agriculture Economic Research Service Urban Influence Codes. Nonrestriction counties of similar urbanicity were chosen to make a comparison population. Temporal trends and county characteristics were accounted for using fixed effects by county and year, as well as linear time trends by county. We adjusted for age, sex, and commuting between restriction and nonrestriction counties.

RESULTS: In 2006, the year before the first restrictions were implemented, there were 8.4 million adults (53.6% female) in highly urban counties with TFA restrictions and 3.3 million adults (52.3% female) in highly urban counties without restrictions. Twenty-five counties were included in the nonrestriction population and 11 in the restriction population. Three or more years after restriction implementation, the population with TFA restrictions experienced significant additional decline beyond temporal trends in MI and stroke events combined (-6.2%; 95% CI, -9.2% to -3.2%; P < .001) and MI (-7.8%; 95% CI, -12.7% to -2.8%; P = .002) and a nonsignificant decline in stroke (-3.6%; 95% CI, -7.6% to 0.4%; P = .08) compared with the nonrestriction populations.

CONCLUSIONS AND RELEVANCE: The NYS populations with TFA restrictions experienced fewer cardiovascular events, beyond temporal trends, compared with those without restrictions.

Comments

  1. Is this blog a new initiative or a hobby?

    ReplyDelete
  2. Re: "Is this blog a new initiative or a hobby?"

    A new initiative. We want to expand the Wolfson's work into neurological disease.

    ReplyDelete

Post a Comment

Popular posts from this blog

Moved to substack

Dear Reader We have moved the preventive neurology unit blog to a new platform called substack . Google is discontinuing its Feedburner and has not added many new features to blogger for some time, which is why we have decided to move the site.  https://preventiveneurology.substack.com/  Thanks Gavin Giovannoni

Are you ready for an EBV vaccine to prevent MS?

"Professor Giovannoni, you tell me that my daughter has a 1 in 40 chance of developing multiple sclerosis and that MS has reached epidemic proportions in parts of the world? Is there anything I can do to reduce her chances of getting MS? Is there anything we can do to stop other people from getting MS?" Although multiple sclerosis (MS) is a complex disease due to the interaction of genetic and environmental factors data on the occurrence of MS at the population level (epidemiology) supports the Epstein Barr Virus (EBV) as being necessary, but not sufficient, for someone to develop MS. In other words, EBV is probably the cause of MS. Of all the putative causative agents that have been proposed to be associated with MS, EBV is the only one where the risk of getting MS if you are EBV negative is close to zero or zero if you limit the analyses to those studies which use a technique called immunofluorescence microscopy as the gold-standard assay to detect anti-EBV antibodies. EBV

The Aducanumab shitstorm

Congratulations to  Al Sandrock , from Biogen, for never giving up on science and for being a  risk-taker extraordinaire .   Photo by Markus Winkler on Unsplash The FDA’s controversial approval of aducanumab for the treatment of Alzheimer’s disease on Monday has caused a shitstorm. The main reason is that in November the FDA’s independent advisory committee voted against recommending approval; they said the data failed to demonstrate persuasively that aducanumab slowed cognitive decline. In a NY Times article Dr Lon Schneider, director of the California Alzheimer’s Disease Center at the University of Southern California and one of the aducanumab site investigators said “This should not be approved, because substantial evidence of effectiveness hasn’t been shown and there’s very little potential that this will address the needs of patients.” What the FDA has done is use the so-called Accelerated Approval Pathway , which allows them to approve a drug for a serious or life-threatening